Dr Anju Peters, an expert in allergy and immunology from Northwestern University, discusses data on new and emerging biologics in rhinosinusitis presented at the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Annual Meeting.
Dr Peters reviews a study examining the effect of dupilumab (Dupixent) on blood eosinophil levels in patients with a range of atopic/allergic diseases; the trial found that hypereosinophilia was rare.
She then addresses two post-hoc analyses of phase 3 dupilumab trials in chronic rhinosinusitis with nasal polyps (CRSwNP). The first examined the impact of the disease on physical and mental health–related quality of life. The second assessed the effect of the drug on both objective and patient-reported subjective endpoints.
Dr Peters closes by discussing two studies that relied on data from the SYNAPSE phase 3 trial of the anti–IL-5 antibody mepolizumab (Nucala) vs placebo in adult patients with CRSwNP. The first looked at the effect of the drug on health-related quality of life, while the second focused on meaningful within-patient changes in disease outcomes.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Clinical Advances in Rhinosinusitis From AAAAI 2021 - Medscape - Mar 22, 2021.
Comments